European ScreeningPort GmbH has announced that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, as part of the New Drugs Fighting Neurological Diseases Consortium (NEU²).
Under the agreement, the European ScreeningPort will use its expertise in order to establish a high-throughput screening assay for a target implicated in multiple sclerosis. This will involve the evaluation of a variety of biochemical and cellular assay formats. Ultimately, it is envisaged that an appropriate high-throughput screening assay can be developed, which can be employed in a small molecule screening campaign to identify starting points for drug discovery.
Multiple sclerosis is one of the most widespread neurological diseases in young adults estimated to affect approximately 2 million people worldwide. The symptoms, onset and progression of these diseases are heterogeneous and their treatment is limited to using disease modifying drugs (DMDs) aiming towards improving the patient's quality of life.
Prof Carsten Claussen, Managing Director comments: "This agreement represents another step forward for the European ScreeningPort being attractive also for the Pharmaceutical industry within new set ups between organizations like us, Academics and the Industry. We will contribute to this project with our expertise and highly flexible approach to challenging projects with the ultimate goal to develop innovative therapies for multiple sclerosis.”